Preparing the Traveler
description
Transcript of Preparing the Traveler
Preparing the Traveler
UNCLASSIFIED
Stephen Thomas, MDDirector, Viral Diseases Branch
Walter Reed Army Institute of ResearchAugust 2013
Paul Keiser, MD, Feb 2014
UNCLASSIFIED Slide 2
Outline
• Introduction: the dynamics of tropical disease• Preparing the traveler
– Ask the right questions– Resources for doctor and patient– Specific advice and preventive measures
• Vaccination• Prevention and self-treatment of traveler’s diarrhea• Chemoprophylaxis of malaria• Vector avoidance• Other
• Conclusion
UNCLASSIFIED Slide 3
Introduction:the dynamics of tropical disease
UNCLASSIFIED Slide 4
Understand the Dynamics of Tropical Diseases
HOST
VECTORS THREATS
Ecology / Environment
Demographics, special
populations
Circulating animal and
human pathogens
Mosquitoes, ticks, bats, birds, dogs, cats, etc.
Temperature, rainfall,
cultural & agricultural
practices, etc.
UNCLASSIFIED Slide 5
Example - Nipah Virus
• Highly pathogenic paramyxovirus– Isolated from CSF– Sungai Nipah village
• Natural hosts are fruit bats
• Causes severe febrile encephalitis
• Outbreaks– Peninsular Malaysia and Singapore (1998 – 1999)– Bangladesh: 2001, 2003, 2004, 2005, 2007 and 2008– India: 2001 and 2007
UNCLASSIFIED Slide 6
Nipah Transmission Dynamics• Pigs crowded in pens• Pens near fruit trees• Fruit bat home destroyed • Fruit bats relocate to fruit trees• Bat fluids contain Nipah • Aerosolized virus infects pigs• Pigs infect handlers
UNCLASSIFIED Slide 7
UNCLASSIFIED Slide 8
Preparing the TravelerAsking the Right Questions
UNCLASSIFIED Slide 9
Asking the Right QuestionsWho, Where, When, Why and What?
• Who is the host / traveler?– Immunologic background, medical problems, etc.
• Where are they going?– Geographic region, known threats.
• When are they going?– Seasonal variations in disease threat epidemiology
• Why are they going there and what will they do?– Defines likely exposure risks– Defines required prophylaxis / PPMs
• Know what you do not know. Look it up. Seek consultation.
UNCLASSIFIED Slide 10
Giving the Right Advice
• Vaccine preventable illness.• Malaria prophylaxis.• Traveler’s diarrhea prevention.• Insect avoidance.• Personal safety.• Behavior and sexual health.• Environmental illness.• Motion sickness and jet lag.• Access to medical care.
UNCLASSIFIED Slide 11
Practice Evidenced Based Medicine
http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Travel%20Medicine.pdf
UNCLASSIFIED Slide 12
Travel Medicine Resources
• U.S. Department of State– www.travel.state.gov
• MILVAX– www.vaccines.mil/QuickReference
• CIA Factbook – www.cia.gov/cia/publications/factbook
• National Center for Medical Intelligence– www.intelink.gov/my.policy
• Travax: AMEDD Virtual Library– https://medlinet.amedd.army.mil
• International Society of Travel Medicine website)– http://www.istm.org/
UNCLASSIFIED Slide 13
US CDC
• http://wwwnc.cdc.gov/travel/
• http://wwwnc.cdc.gov/travel/yellowbook/2014/table-of-contents
UNCLASSIFIED Slide 14
DoD On-Line Infectious Diseases Consults• [email protected]
• [email protected]• [email protected]• [email protected]
• Began in January 2005• 839 teleconsultations thru July 2013• 35 teleconsultations received January – July 2013• 6 teleconsultations received in July 2013• First teleconsultation received from Niger• 7.4% of all teleconsultations received in the AKO Program
UNCLASSIFIED Slide 15
Key Elements of the Consult• •Patient History
– When did it start– Patient symptoms now?– Getting better? Worse? Staying the same?
Spreading?– Previous treatments and outcomes?– Laboratory tests results (if any)?– Your Dx / DDx– Your question
•Limitations you have in managing the patient15
UNCLASSIFIED Slide 16
Locations Submitting Teleconsultations
Supported Facility
US, Canadian& AustralianNavy afloat
Afghanistan
Bosnia
Chad
Continental US
Egypt – MFO Sinai
Haiti Relief
Germany
Hurricane KatrinaIraqItaly - Sicily
KuwaitKyrgyzstan
OkinawaPakistan
Qatar
Niger
United Arab Emirates
TurkeyDjiboutiEcuador
Morocco
Belize Philippines
JapanCongo
MauritaniaSenegal
Papua New Guinea
AlbaniaGhana
Guatemala
Botswana
Turkmenistan
BahrainThailand
GuineaMali
Guam
SpainHonduras
Yemen
LaosBelgium
UkraineEl Salvador
KenyaBangladesh
Jordan
Saudi Arabia
Sudan
Solomon Islands
Ethiopia
Chili
http://www.cia.gov/cia/publications/factbook/reference_maps/pdf/time_zones.pdf
Peru
Nepal
UNCLASSIFIED Slide 17
Key Elements of the Consult• •Patient Demographics
– Age– Gender– Branch of service (if not MIL, state their nationality)– Identify if contractor, detainee, foreign military, etc.
•Include digital images if appropriate • PDFs of EKGs• JPEGs of radiographs• Copies of laboratory and pathology reports
• Do not send any patient identifying info(HIPAA applies)
UNCLASSIFIED Slide 18
UNCLASSIFIED Slide 19
Preparing the TravelerVaccination
UNCLASSIFIED Slide 20
Vaccination• Confirm up-to-date routine vaccinations for adults
– Countries that do not routinely vaccinate may have higher incidences of vaccine-preventable diseases.
• Confirm past travel related vaccination history
• Calculate risk: benefit ratio– Disease threat versus vaccine adverse event.– Pre-existing immunity
• Consider special populations– Pregnant, immunosuppressed, history of adverse
vaccine reactions
UNCLASSIFIED Slide 21
Vaccine Preventable Diseases (Routine)
http://www.cdc.gov/vaccines/schedules/downloads/adult/mmwr-adult-schedule.pdf
UNCLASSIFIED Slide 22
Vaccine preventable diseases for which a marker for protection exists.
Kelso JM, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012 Jul;130(1):25-43.
UNCLASSIFIED Slide 23
Hepatitis A
• A cell culture–adapted virus, inactivated with formalin, and adsorbed to an aluminum hydroxide adjuvant.
• Protective antibody levels develops within 4 weeks of the first dose in 95%; a second dose given >6 months later confers lasting immunity in >99%.
• Licensed in 1995; part of the routine childhood vaccination schedule in the US since 2005.
• Available in pediatric (0.5 mL) and adult (1.0 mL) formulations.
UNCLASSIFIED Slide 24
Hepatitis A
• Concomitant IMIG should be considered for:– Unvaccinated adults > 40 years of age, immuno-
compromised persons and those with chronic liver disease planning to travel in < 2 weeks.
– Travelers who choose not to receive the vaccine.
• IMIG (0.02 mL/kg) provides protection against HAV infection for up to 3 months.
– Persons traveling > 2 months should get 0.06 mL/kg. – Repeat dose after 5 months for prolonged travel.
UNCLASSIFIED Slide 25
Japanese Encephalitis
• An inactivated Vero cell culture–derived vaccine.• The two dose IM series (days 0 and 28) should be
completed ≥1 week before travel.• Vaccination is only recommended for long-term travelers
or those at increased risk of exposure to mosquitoes in rural areas.
• A booster should be given if recurrent risky travel occurs >1 year after the primary series.
UNCLASSIFIED Slide 26
Japanese Encephalitis
• Headache, myalgia, fatigue, and an influenza-like illness were each reported at a rate of >10%.
• Approved in 2009 for adults and in 2013 for children down to age 2 months
• Dose is based on age:– 2 months to 2 years old get 0.25mL– > 2 years old get 0.5mL.
UNCLASSIFIED Slide 27
THE ASSISTANT SECRETARY OF DEFENSE 1200 DEFENSE PENTAGON WASHINGTON, DC 20301-1200
HEALTH AFFAIRS MAY 07 2013
“3. We advise recommendation of JE vaccine for the following Service members and beneficiaries:
– Short-term (<1 month) travelers to endemic areas during the JE transmission season if they plan to travel outside of an urban area and have an increased risk for JE exposure. 1. spending substantial time outdoors in rural or agricultural areas, especially during the evening or night;2. participating in extensive outdoor activities (e.g., camping, hiking, trekking, biking, fishing, hunting, or farming); and3. staying in accommodations without A/C, screens, bed nets.
– Travelers to an area with an ongoing JE outbreak;– Travelers to endemic areas who are uncertain of specific destinations,
activities, or duration of travel; and– Laboratory workers with potential exposure to infectious JE virus.”
UNCLASSIFIED Slide 28
Meningococcus
• Purified capsular polysaccharides from four disease-causing serogroups: A, C, W, Y.
• Protein-conjugated (MCV4) formulations available for ages 2 months to 55 years, given IM.
• Unconjugated (MPSV4) vaccine is given SC.• The surrogate marker for protection (bactericidal antibody
titer) is not commercially available.– Titers can be ordered in CHCS, but this is not a
bactericidal assay.– These titers are used to evaluate antibody deficiencies,
not to indicate immunity to meningococcal disease.• Licensed in 1978; a routine childhood vaccine since 2005.
UNCLASSIFIED Slide 29
Meningococcus
• The risk to travelers varies by location and season– Group A predominates in sub-Saharan Africa.– Risk is highest during the dry season (Dec-June).– Other epidemics are reported through various travel
resources including http://wwwnc.cdc.gov/travel/.• The Saudi government requires Hajj/Umrah visitors to
present proof of vaccination:– Tetravalent vaccination for ages >2 years.
• Vaccination must be within last 3 years.– Group A vaccination for ages 3 mos to <2 years. – Visitors coming from the African meningitis belt will
also be administered chemoprophylaxis.
UNCLASSIFIED Slide 30
Polio
• Oral polio vaccine is not available in the US.– Live virus is shed in the stool.– May lead to secondary immunization, which can be
advantageous in austere environments where 100% vaccination coverage is difficult.
– May also lead to vaccine associated paralytic polio (1-2 cases / million first-time vaccine recipients).
– Discontinued in the US in 2000.
UNCLASSIFIED Slide 31
Polio
• Trivalent inactivated polio vaccine is available in the US.– Covers all three serotypes– Grown in Vero cells, inactivated with formaldehyde.
• Recommended doses:– Unvaccinated adults: 3 doses, months 0,1 6-12.– Adults completely vaccinated as children: 1 dose.– Incompletely vaccinated adults: finish the 3-dose
series.
UNCLASSIFIED Slide 32
Rabies
• Pre-exposure vaccination may be considered for travelers to enzootic areas with limited access to healthcare.
• Two inactivated vaccines are available.– human diploid cell rabies vaccine (HDCV)– purified chick embryo cell (PCECV) vaccine
• Pre-exposure regimen is 3 doses, days 0, 7, 21 or 28.• Given IM:
– Not in the buttock.– ID formulation not available in the US, but in use and
shown to be effective elsewhere.
UNCLASSIFIED Slide 33
Rabies
• Need for post-exposure prophylaxis is determined by the WHO category of exposure
• Category I – touching or feeding animals, licks on the skin
• Category II - nibbling of uncovered skin, minor scratches or abrasions without bleeding, licks on broken skin
• Category III – single or multiple transdermal bites or scratches, contamination of mucous membrane with saliva from licks; exposure to bat bites or scratches
UNCLASSIFIED Slide 34
Rabies
• Post-exposure regimen for category II and III– With pre-exposure vaccination
• Two boosters of a cell culture vaccine (days 0, 3).– Without pre-exposure vaccination
• Four doses of cell culture vaccine (days 0,3,7,14).• For category III exposures, also inject human RIG into the wound and IM (20 IU/kg)
UNCLASSIFIED Slide 35
Typhoid
• Two vaccines are available, each with 50-80% efficacy:– Oral live attenuated vaccine (from the Ty21a strain)
• Four doses, taken on alternate days.• Complete at least one week before travel.• Must be kept refrigerated.• Do not administer with antibiotics (mefloquine and chloroquine are okay; proguanil is not).
• Not approved for children <6.• Not for the immunocompromised.• May cause nausea, other GI symptoms.• Boost (with the same regimen) after 5 years if needed.
UNCLASSIFIED Slide 36
Typhoid
• Two vaccines are available, each with 50-80% efficacy:– IM Vi capsular polysaccharide (ViCPS)
• Approved down to age two.• Administer at least 2 weeks before travel.• Frequently associated with pain (>95%), headache (16-20%), malaise.
• Boost after 2 years.
UNCLASSIFIED Slide 37
Yellow Fever
• A live attenuated vaccine, prepared by culturing the a 17D strain of yellow fever virus in chicken embryos.
– Hypersensitivity to eggs is a contraindication.• No preservative; the vaccine must be reconstituted
immediately before use.• One subcutaneous dose every 10 years as needed.• Mild systemic reactions are common (10-30%).• Use with caution in the immunosuppressed.
– Thymic disorders, HIV, malignancy, transplant– Immunosuppressive drugs and biologicals.– Family members of immunocompromised patients
can receive the vaccine.
UNCLASSIFIED Slide 38
Yellow Fever• YF vaccine–associated neurologic disease.
– Includes disseminated infection and non-infectious complications such as Guillain-Barre and Bell’s palsy.
– Incidence is age-related;• 0.8/100,000 doses overall; >50/100,000 doses in infants; 2.3/100,000 for age >70.
• Has occurred in breast-fed infants of vaccinated mothers.
– Rarely occurs with booster doses.• YF vaccine–associated viscerotropic disease
– Disseminated infection similar to wild-type disease.– 2.3/100,000 doses for age>70.– Does not occur with booster doses.
UNCLASSIFIED Slide 39
Yellow Fever
• Administer 30 days apart from MMR.• No decrease in efficacy if given with IMIG.• Proof of vaccination:
– May be required for entry into• Endemic countries, to prevent illness.• Non-endemic countries, to prevent importation.
– Traveler’s with vaccine contraindications may require a waiver letter to be permitted entry.
– Traveler’s with inadequate documentation may be quarantined, typically for six days.
UNCLASSIFIED Slide 40
Yellow Fever
UNCLASSIFIED Slide 41
Yellow Fever
UNCLASSIFIED Slide 42
Vaccination Adverse Events
• Avoid live-attenuated vaccines in immunocompromised travelers.
• Anaphylaxis to vaccines occurs about 1/million doses.– Patients should be monitored post-vaccination.– Epinephrine should be available.
• Patients with contact allergies to vaccine components (neomycin) can generally receive parenteral vaccines.
UNCLASSIFIED Slide 43
Vaccination: General comments• Live-virus vaccines should be administered together or >4
weeks apart.– Administering a live-virus vaccine within 4 weeks after
administration of another live-virus vaccine can decrease immunogenicity to the second vaccine.
UNCLASSIFIED Slide 44
Preparing the TravelerDiarrhea
UNCLASSIFIED Slide 45
Traveler’s Diarrhea (TD)• Attack rates range from 30% to 70% of travelers• Clinical syndrome from a variety of intestinal pathogens
– Bacterial pathogens are the predominant risk (80%–90%)– Viruses have been isolated (5%–8%), Norovirus may > %– Protozoal pathogens (10%), longer-term travelers
• Bacteria– Enterotoxigenic Escherichia coli (#1), Campylobacter jejuni,
Shigella spp., and Salmonella spp. Enteroadherent and other E. coli species are also common. Aeromonas spp. and Plesiomonas spp. as well.
• Viral– Norovirus, rotavirus, and astrovirus.
• Protozoal– Giardia, Entamoeba histolytica and Cryptosporidium uncommon– Cyclospora (Nepal, Peru, Haiti, and Guatemala)– Dientamoeba fragilis is a low-grade but persistent pathogen
UNCLASSIFIED Slide 46
Hepatitis E
UNCLASSIFIED Slide 47
Traveler’s Diarrhea (TD)• Prevention
– Food and beverage selection• Wash it, boil it ,cook it, peel it: reduces, does not eliminate risk
– Non-antimicrobial drugs for prophylaxis• Bismuth subsalicylate (Pepto-Bismol)
– Not in travelers w/ aspirin allergy, renal insufficiency, or gout.– Not for use with anticoagulants, probenecid, or methotrexate. – Not generally recommended for children aged <12.– Studies have not established safety for periods >3 weeks.
– Prophylactic Antibiotics• Diarrhea attack rates are reduced by 90% or more• At this time, prophylactic antibiotics not recommended for most• Ease of treating diarrhea versus side effects of antibiotics
UNCLASSIFIED Slide 48
UNCLASSIFIED Slide 49
Preparing the TravelerMalaria
UNCLASSIFIED Slide 50
Malaria
UNCLASSIFIED Slide 51
Malaria
UNCLASSIFIED Slide 52
Mefloquine Resistance
UNCLASSIFIED Slide 53
Malaria
• MALARIA KILLS SERVICE MEMBERS!
• #1 threat if you are traveling to a malarious region
• Any fever in any traveler who is in or who has been to a malarious region has malaria until proven otherwise
UNCLASSIFIED Slide 54
Marines deploy to Liberia, 44 contract malaria despite prophylaxis and PPMs
UNCLASSIFIED Slide 55
Preparing the TravelerVector Avoidance
UNCLASSIFIED Slide 56
Vector Avoidance• Mosquitoes, sand flies, chiggers, ticks
• Malaria, arboviruses, rickettsiae, leishmaniasis
• Be smart, be knowledgeable, be safe– Geographic areas with known risk– Avoid man-made creation of local breeding areas– Understand feeding habits
• Protect yourself
UNCLASSIFIED Slide 57
DoD Repellent System
UNCLASSIFIED Slide 58
(Woodland) NSN 3740-01-516-4415 (Desert) NSN 3740-01-518-7310
• Fits on standard cot
• Set-up: throw it
• Self-supporting
• No cot or pole set needed
• Zips open and closed on both sides
• Factory-treated with permethrin – 25
washings or one year
• Has attached floor for use on ground
• Water resistant
• Flame retardant
• 2 pounds
Pop-Up Bednet
UNCLASSIFIED Slide 59
Preparing the TravelerAdditional Risks
UNCLASSIFIED Slide 60
Additional Concerns• Trauma
– Motor vehicle accidents– Wear a belt, helmet, 4 wheels when possible
• Water exposure– Rip tide and undertow– Infectious diseases (leptospirosis, shistosomiasis)
• Sexually transmitted infections– HIV, resistant organisms– Human trafficking
• Environment– Heat, cold, altitude
• Alcohol and drugs– Bad decisions, dangerous decisions
UNCLASSIFIED Slide 61
Preparing the TravelerConclusion
UNCLASSIFIED Slide 62
Differences Between CIV and MIL Populations
UNCLASSIFIED Slide 63
Differences Between CIV and MIL Populations
UNCLASSIFIED Slide 64
Differences Between CDC and US military’s use of malaria chemoprophylaxis
UNCLASSIFIED Slide 65
Differences Between CDC and US military’s use of malaria chemoprophylaxis
UNCLASSIFIED Slide 66
Differences Between CDC and US military’s use of malaria chemoprophylaxis
UNCLASSIFIED Slide 67
The Ten Commandments of Travel Medicine• Acquire a pre-travel consultation from your provider• Wash your hands and avoid eating poop• Vaccinate• Invest in DEET, PPMs• Respect traffic, local rules• Don’t drink and do anything• Respect and believe fever• Stay away from animals• Avoid STIs • Take your prophylaxis
• KNOW WHAT YOU DON’T KNOW!